Articles
Media
Publications
Conferences
CME/CE
Resources
Subscribe

Spotlight -

ZEISS Clinical Cases|

Heidelberg Engineering: Enhancing the Patient Journey

Opinion|Videos|February 7, 2025

Outcomes with Raricimab and Choosing Between the New Therapies

Author(s)John Kitchens, MD, Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth, Michael W. Stewart, MD

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.

Episodes in this series

3 experts are featured in this series.

EP. 1 Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

3 experts are featured in this series.

EP. 2 Advantages of the Molecular Structure of Aflibercept

3 experts are featured in this series.

EP. 3 Treat-and-Extend Strategy With Aflibercept

3 experts are featured in this series.

EP. 4 Assessing New Therapies for Retinal Diseases

3 experts are featured in this series.

EP. 5 Significance of the Higher Molar Dose of Aflibercept 8 mg

3 experts are featured in this series.

EP. 6 Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

3 experts are featured in this series.

EP. 7 Patient Selection for Aflibercept 8 mg

3 experts are featured in this series.

EP. 8 Faricimab Molecular Design and Role of Ang-2

3 experts are featured in this series.

EP. 9 Outcomes with Raricimab and Choosing Between the New Therapies

3 experts are featured in this series.

EP. 10 Safety Profile of New Therapies

3 experts are featured in this series.

EP. 11 Perspectives on the Usefulness of Real-world Data

3 experts are featured in this series.

EP. 12 Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

3 experts are featured in this series.

EP. 13 Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

In clinical trials, faricimab showed noninferior vision outcomes compared to aflibercept 2 mg. What added benefit do you see by targeting Ang-2?

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Content

Beyond anti-VEGF: The next wave in retinal therapy

ByMark Barakat, MD

June 18th 2026

Opuviz aflibercept biosimilar debuts in Europe for retinal disease treatment

ByLucia Gambuzza

June 2nd 2026

(Image credit: AdobeStock/Alberto Gonzalez) Allied health professional-led keratoconus service shows safe outcomes in UK tertiary centre

Allied health professional-led keratoconus service shows safe outcomes in UK tertiary centre

BySheryl Stevenson

May 29th 2026

(Image credit: AdobeStock/valeo5) First commercial FLIGHT procedures performed as ViaLase begins European launch

First commercial FLIGHT procedures performed as ViaLase begins European launch

BySheryl Stevenson

May 28th 2026

(Image credit: AdobeStock/Antonio) Rethinking SLT: From pressure reduction to biological activation

Rethinking SLT: From pressure reduction to biological activation

ByFrancisco Fernando Suñe, MD

May 5th 2026

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Jacob Lang, OD, FAAO; Selina R. McGee, OD, FAAO; Neda Shamie, MD

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

John D. Gelles, OD, FAAO, FIAOMC, FCLSA, FSLS, FBCLA; John Hovanesian, MD, FACS

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Arjan Hura, MD; Neda Shamie, MD; Kristin Barnes, OD

Retina Updates in Montréal

In-Person + Virtual Event

Retina Updates in Montréal

July 16-17, 2026

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Mark Schaeffer, OD, FAAO; Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO, FAAOMS; Selina R. McGee, OD, FAAO

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Trending on Ophthalmology Times Europe

Beyond anti-VEGF: The next wave in retinal therapy

ZEISS reports early implantations of AT LUCIA Toric 721P IOL in Europe

Time is vision: Act fast after ocular chemical burns